Navigation Links
Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent

WELLESLEY HILLS, Mass., May 17 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the MRI imaging intellectual properties of the EP-3600 MRI imaging agent, which will be auctioned on May 28, 2010, include potential royalties of 2% each from the development and commercialization of three additional programs related to MRI imaging agents and/or technologies.  There is also a fourth program related to one MRI imaging agent with a potential royalty of 4-6% from the development and commercialization with a buy-up option to increase royalties up to 15-17%.  Furthermore, the purchase of EP-3600 also includes the rights to develop and commercialize collagen binding therapeutics using the same proprietary technology that resulted in the discovery of EP-3600.  Collagen binding therapeutics could be targeted toward the treatment of debilitating diseases such as scleroderma.  

The assets of Epix were transferred to him on July 20, 2009 and he is liquidating them for the benefit of Epix creditors.  He recently reached an agreement with Bayer Schering Pharma that permits the sale of the MRI imaging programs.  

EP-3600 and related analogs are gadolinium-based MRI imaging agents with a potential indication for myocardial perfusion imaging.  These lead compounds represent first-in-class collagen binding agents that are currently in preclinical development.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - IPSALESERVICES@FINNWARNKEGAYTON.COM or 781-237-8840.  They will then receive a bid package and access to an electronic data room.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the owner of the firm Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years.  His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or IPSALESERVICES@FINNWARNKEGAYTON.COM

SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 ... Pipeline Review, H2 2015 market research report provides ... pipelines by identifying new targets and MOAs to ... . --> . ... spread across 62 pages, analyzing 6 companies, 8 ...
(Date:10/12/2015)... , Oct. 12, 2015 Device usage ... need to help integrate these devices into existing clinical ... ergonomic healthcare mounting and mobility solutions, has launched the ... cart yet, for a wide array of laptops and ... SV10 was developed exclusively for Microsoft Surface and is ...
(Date:10/12/2015)... 2015  Today, Divurgent is honored to announce Paul ... former CIO, Paul brings 15 years of hands-on experience as ... with today,s CIOs, he is one. The challenges that face ... faced, and his new role with Divurgent allows him to ... an organization. ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... American Family Care (AFC), the nation’s ... by opening its 151st medical center. Located at 606A Boll Weevil Circle in Enterprise, ... continue fulfilling our mission of making quality health care accessible and economical with the ...
(Date:10/12/2015)... ... October 12, 2015 , ... At first glance, it looks ... one would find atop a drink in a tiki bar. But the Parachute® Ventricular ... at Allegheny General Hospital (AGH) could potentially signal a new way of treating people ...
(Date:10/12/2015)... IL, USA (PRWEB) , ... October 12, 2015 ... ... high-fidelity personal audio products, will present the latest version of Companion Mics, the ... for audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) 60th Annual ...
(Date:10/12/2015)... ... October 12, 2015 , ... FEI ... workforce resilience from EAP to crisis management, will present a session at the ... Wisconsin, Oct. 14-16, 2015. , FEI’s Chief Operating Officer Daniel Potterton will present ...
(Date:10/12/2015)... ... October 12, 2015 , ... To help raise awareness this ... to the National Breast Cancer Foundation. The National Breast Cancer Foundation is dedicated ... early detection, education, and support services. , The annual campaign to increase breast ...
Breaking Medicine News(10 mins):